NEW YORK – Colossal Biosciences said Wednesday that it has secured $200 million in Series C funding.
The round was jointly led by TWG Global, Mark Walter, and Thomas Tull, bringing the company's total funding to date to $435 million.
With the money raised, Colossal said it will continue to advance its genetic engineering technologies while developing new software, wetware, and hardware solutions that will enable applications beyond de-extinction including species preservation and human healthcare.
"This funding will grow our team, support new technology development, expand our de-extinction species list while continuing to allow us to carry forth our mission to make extinction a thing of the past," Colossal CEO and Cofounder Ben Lamm said in a statement.
A spinout from George Church's lab at Harvard Medical School and the Wyss Institute, Colossal said it currently employs over 170 scientists and partners with labs in Boston, Dallas, and Melbourne, Australia.
The company said it is working to tackle challenging problems in biology, including mapping genotypes to traits and behaviors, understanding developmental pathways to phenotypes, and developing new tools for multiplex and large-insert genome engineering.
The de-extinction firm launched in late 2021 with $15 million in seed funding and later raised $60 million in Series A funding in March 2022. In January 2023, the company secured an additional $150 million in a Series B round.
In October, Colossal launched the Colossal Foundation with $50 million in funding from private investors to focus on the application of the company's technology through partnerships for species that can benefit from genetic rescue, biobanking, and the creation and use of reference genomes.